 AstraZeneca PLC LON:AZN said its planned acquisition of rare disease specialist Alexion Pharmaceuticals Inc has been cleared by the US Federal Trade Commission. The FTSE 100 pharma giant said the approval follows similar clearances in Canada, Brazil, Russia and other countries globally, with additional regulatory clearances still pending from territories including the UK, the EU and Japan. 